AADI Aadi Biosciences
- 1.960
- -0.030-1.51%
- 1.950
- -0.010-0.51%
Aadi Biosciences News
Earnings Preview: AADI to Report Financial Results on November 06
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
Express News | The Arbitration Panel Issued A Final Award Which Found And Concluded That Aadi Bioscience Did Not Breach The EOC Pharma License Agreement And Accordingly Is Not Liable For Any Damages To EOC - Filing
Aadi Bioscience Downgraded to Neutral, Shares Fall
Piper Sandler Downgrades Aadi Biosciences(AADI.US) to Hold Rating, Cuts Target Price to $1.75
Express News | Aadi Bioscience Inc : Piper Sandler Cuts to Neutral From Overweight
Express News | Aadi Bioscience Inc - Desai Will Continue to Serve as a Member of Board
Express News | Aadi Bioscience Inc - on August 20, Neil Desai, Was Notified That His Employment as Executive Chairman of Company Will Cease on October 1, 2024
Express News | Aadi Bioscience Inc - Board Has Determined That Itri's Pending Cessation of Employment Is a Voluntary Resignation
Express News | Aadi Bioscience - on Aug 16, Loretta Itri, M.d. Notified Board That Her Employment as Chief Medical Officer Will Cease Effective October 1, 2024
Aadi Bioscience Cut to Hold at Jefferies Following Fyarro Failure in Solid Tumors
Jefferies Downgrades Aadi Bioscience to Hold From Buy
Express News | Aadi Bioscience Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $1.5 From $11
This American Express Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Traders Await Fed Minutes as US Equity Futures Post Narrow Gains Pre-Bell
Express News | HC Wainwright & Co. Reiterates Neutral on Aadi Bioscience
Aadi Bioscience Analyst Ratings
Express News | Aadi Bioscience Shares Are Trading Lower After the Company Announced an Analysis by the Independent Data Monitoring Committee Demonstrated That the Study Was Unlikely to Exceed an Efficacy Threshold Necessary to Support an Accelerated Approval. The...
Top Premarket Decliners
Analysis
Price Target
No Data
No Data